<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Devalued and Distrusted : Can the Pharmaceutical Industry Restore Its Broken Image?</title>
  </titleInfo>
  <name type="personal">
    <namePart>LaMattina, John L.</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="marc">bibliography</genre>
  <genre authority="">Electronic books.</genre>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">nju</placeTerm>
    </place>
    <place>
      <placeTerm type="text">Hoboken, New Jersey</placeTerm>
    </place>
    <publisher>Wiley</publisher>
    <dateIssued>[2013]</dateIssued>
    <dateIssued encoding="marc">2013</dateIssued>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <form authority="gmd">electronic resource</form>
    <extent>1 online resource (ix, 125 pages)</extent>
  </physicalDescription>
  <abstract>"While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R &amp; D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"--</abstract>
  <tableOfContents>1. The four secrets the drug companies don't want you to know -- 2. What has happened to R &amp; D productivity? -- 3. Key therapeutic areas for improving health -- 4. Improving R &amp; D output -- 5. Restoring pharma's image -- 6. Final thoughts.</tableOfContents>
  <note type="statement of responsibility">John L. LaMattina, PhD.</note>
  <note>Includes index.</note>
  <note>Machine generated contents note: Introduction Part 1. "The 4 secrets that drug companies don't want you to know" part 2. What has happened to R &amp; D productivity? a. impact of mergers b. impact of FDA c. impact of payers Part 3. Challenges in key therapeutic areas for improving health a. cancer b. diseases of the brain c. cardiovascular disease d. diabetes e. bacterial Infections part 4. Improving R &amp; D output a. view of others b. personal vision part 5. Restoring the pharma image part 6. Final thoughts.</note>
  <note>Includes bibliographical references and index.</note>
  <subject authority="lcsh">
    <topic>Pharmaceutical industry</topic>
    <topic>Corrupt practices</topic>
  </subject>
  <subject>
    <topic>Medical</topic>
  </subject>
  <subject authority="bisacsh">
    <topic>MEDICAL</topic>
    <topic>Pharmacology</topic>
  </subject>
  <subject authority="fast">
    <topic>Pharmaceutical industry</topic>
    <topic>Corrupt practices</topic>
  </subject>
  <classification authority="lcc">HD9665.5 .L36 2013eb</classification>
  <classification authority="ddc" edition="23">338.4/76151</classification>
  <relatedItem type="otherFormat" displayLabel="Print version:">
    <titleInfo>
      <title>Devalued and distrusted</title>
    </titleInfo>
    <name>
      <namePart>LaMattina, John L.</namePart>
    </name>
    <originInfo>
      <publisher>Hoboken, New Jersey : John Wiley &amp; Sons, Inc., [2013]</publisher>
    </originInfo>
    <identifier type="local">(DLC)  2012032915</identifier>
    <identifier type="local">(OCoLC)811597120</identifier>
  </relatedItem>
  <identifier type="isbn">9781118487471</identifier>
  <identifier type="isbn">1118487478</identifier>
  <identifier type="isbn">9781283917421</identifier>
  <identifier type="isbn">1283917424</identifier>
  <identifier type="isbn">9781118511251</identifier>
  <identifier type="isbn">1118511255</identifier>
  <identifier type="isbn">9781118511299</identifier>
  <identifier type="isbn">1118511298</identifier>
  <identifier type="isbn">9781118511329</identifier>
  <identifier type="isbn">1118511328</identifier>
  <identifier type="issue number">EB00063788 Recorded Books</identifier>
  <identifier type="stock number">684D5251-34C3-4198-A03A-18F445996D72 OverDrive, Inc.</identifier>
  <identifier type="uri">http://onlinelibrary.wiley.com/book/10.1002/9781118511329</identifier>
  <location>
    <url>http://onlinelibrary.wiley.com/book/10.1002/9781118511329</url>
  </location>
  <recordInfo>
    <recordContentSource authority="marcorg">AZU</recordContentSource>
    <recordCreationDate encoding="marc">121010</recordCreationDate>
    <recordChangeDate encoding="iso8601">20171107082433.0</recordChangeDate>
    <recordIdentifier source="OCoLC">ocn831464032</recordIdentifier>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
